New study examines U.S. trends in body mass index and obesity and finds improving numbers, driven in part by GLP-1 weight-loss drugs.

New research shows GLP-1 agonists, like Ozempic, and SGLT2 inhibitors, like Farxiga, help lower the risk of secondary stroke, heart attack and death in stroke survivors.

A new study finds semaglutide, the active ingredient in Ozempic and Wegovy, reduced kidney damage by up to 52% in people with obesity.

Researchers are now testing a new semaglutide delivery platform that combines the medication with a special hydrogel to achieve sustained release over one month or longer.

Pregnant women with high levels of PFAS chemicals commonly found in consumer products may experience weight and heart issues later in life.

A new study finds overweight people who stay awake too late face higher odds of metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke and diabetes.

A new study led by researchers at the American Cancer Society finds 40% of cancer cases and about half of all cancer deaths are caused by potentially modifiable risk factors.